Journal of Clinical Endocrinology & Metabolism, Vol 79, 1256-1260, Copyright © 1994 by Endocrine Society

ARTICLES

Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects

PJ Schmidt, RH Purdy, PH Moore Jr, SM Paul and DR Rubinow
Section on Behavioral Endocrinology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892.

The levels of 3 alpha-hydroxy-5 alpha-pregnan-20-one (allopregnanolone) and the epimeric 3 alpha-hydroxy-5 beta-pregnan-20-one (pregnanolone) were studied in women with prospectively confirmed premenstrual syndrome (n = 15) and in a group of asymptomatic control women (n = 12) during the luteal phase of the menstrual cycle. Single late luteal phase plasma samples were selected to make comparisons of plasma hormone levels between patients and controls in the following measures: allopregnanolone, pregnanolone, the ratio of allopregnanolone to pregnanolone, the ratio for each of these anxiolytic steroids to the parent compound progesterone, and the ratio of the sum of allopregnanolone and pregnanolone to progesterone. Differences in these measures were compared by analysis of variance. Additionally, correlations were performed among the various hormone measures and between the hormone measures and the symptom self-ratings. Analysis of variance showed no significant between group differences in the plasma levels of allopregnanolone, pregnanolone, and progesterone. Plasma levels of both allopregnanolone and pregnanolone were correlated with plasma progesterone levels. However, there were no significant correlations between the severity of mood and behavioral symptoms and plasma levels of progesterone, allopregnanolone, and pregnanolone. These data suggest that symptoms of premenstrual syndrome are not associated with a simple deficiency state of either progesterone or its anxiolytic steroid metabolites.

This article has been cited by other articles:

				X. Protopopescu, H. Pan, M. Altemus, O. Tuescher, M. Polanecsky, B. McEwen, D. Silbersweig, and E. Stern Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle PNAS, November 1, 2005; 102(44): 16060 - 16065. [Abstract] [Full Text] [PDF]

				K. Pazol, M. E. Wilson, and K. Wallen Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2998 - 3006. [Abstract] [Full Text] [PDF]

				R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF]

				F.-C. Hsu and S. S. Smith Progesterone Withdrawal Reduces Paired-Pulse Inhibition in Rat Hippocampus: Dependence on GABAA Receptor alpha 4 Subunit Upregulation J Neurophysiol, January 1, 2003; 89(1): 186 - 198. [Abstract] [Full Text] [PDF]

				C. N. Epperson, K. Haga, G. F. Mason, E. Sellers, R. Gueorguieva, W. Zhang, E. Weiss, D. L. Rothman, and J. H. Krystal Cortical {gamma}-Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder: A Proton Magnetic Resonance Spectroscopy Study Arch Gen Psychiatry, September 1, 2002; 59(9): 851 - 858. [Abstract] [Full Text] [PDF]

				E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF]

				P. Follesa, M. Serra, E. Cagetti, M. G. Pisu, S. Porta, S. Floris, F. Massa, E. Sanna, and G. Biggio Allopregnanolone Synthesis in Cerebellar Granule Cells: Roles in Regulation of GABAA Receptor Expression and Function during Progesterone Treatment and Withdrawal Mol. Pharmacol., June 1, 2000; 57(6): 1262 - 1270. [Abstract] [Full Text]

				C. N. Epperson, K. L. Wisner, and B. Yamamoto Gonadal Steroids in the Treatment of Mood Disorders Psychosom Med, September 1, 1999; 61(5): 676 - 697. [Abstract] [Full Text] [PDF]

				A. R. Genazzani, F. Petraglia, F. Bernardi, E. Casarosa, C. Salvestroni, A. Tonetti, R. E. Nappi, S. Luisi, M. Palumbo, R. H. Purdy, et al. Circulating Levels of Allopregnanolone in Humans: Gender, Age, and Endocrine Influences J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2099 - 2103. [Abstract] [Full Text]

				V. Uzunova, Y. Sheline, J. M. Davis, A. Rasmusson, D. P. Uzunov, E. Costa, and A. Guidotti Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine PNAS, March 17, 1998; 95(6): 3239 - 3244. [Abstract] [Full Text] [PDF]